Erica Jordan is Chief Commercial Officer at Revance Therapeutics, Inc. (RVNC). They have made 1 open-market trade across 1 company since 2024, most recently 2025-02-06.
CIK 0002012846
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RVNC | 107,942 | $394K |
Shares reported on the most recent Form 4, priced at the 2025-02-06 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RVNC | SELL | 2024-04-16 | 2024-04-17 | $3.80 | $9K | -1.6% | -19.5% | +13.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.